Alamar Biosciences financials
$27.39−9.36%
Close Nov 4, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 |
|---|---|
| Revenue | $29.4M |
| Gross profit | $17.7M |
| Gross margin | 60.2% |
| Operating income | -$13.5M |
| Net income | -$13.2M |
| Net margin | −44.9% |
| Diluted EPS | $-0.22 |
| EBITDA | -$12.4M |
| Operating cash flow | -$11.3M |
| Free cash flow | -$15.0M |
| Diluted shares | 58.7M |
Balance sheet
| Period end | Jun 30 |
|---|---|
| Cash & equivalents | $133.0M |
| Short-term investments | $117.1M |
| Total debt | $9.9M |
| Total assets | $391.0M |
| Total liabilities | $78.1M |
| Shareholders' equity | $312.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology